Market Spotlight: Glioblastoma (GBM)
Market Spotlight: Glioblastoma (GBM)
$1,318.00
This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 77,000 incident cases of glioblastoma worldwide, and forecasts that number to increase to 91,800 incident cases by 2028.
- It is estimated that the majority of diagnosed cases were in males in 2019. Approved drugs in the glioblastoma space focus on DNA, vascular endothelial growth factor, DNA synthesis, protein synthesis, and RNA synthesis. These drugs are administered via the intravenous, intraocular, subretinal, subconjunctival, intratumoral, and oral routes for glioblastoma.
- The majority of industry-sponsored drugs in active clinical development for glioblastoma are in Phase II, with only one drug in the NDA/BLA phase.
- Therapies in mid- and late-stage development for glioblastoma focus on a wide variety of targets. The majority of pipeline drugs for glioblastoma are administered via the oral and intravenous routes.
- High-impact upcoming events for drugs in the glioblastoma space comprise topline Phase I trial results for KB004; topline Phase I/II trial results for Calquence and EO2401; topline Phase II trial results for lisavanbulin and ABI-009; Phase III updated trial results for DCVax-Brain and Trans Sodium Crocetinate (TSC); and an expected PDUFA date for biosimilar bevacizumab (Mylan/Biocon).
- The overall likelihood of approval of a Phase I solid tumors asset is 5.5%, and the average probability a drug advances from Phase III is 42.7%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for glioblastoma have been in the early and mid-phases of development, with 92% of trials in Phase I–II, and only 8% in Phase III–IV.
- The US has a substantial lead in the number of glioblastoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the glioblastoma space is dominated by completed trials. Merck & Co has the highest number of completed clinical trials for glioblastoma, with 81 trials.
- Merck & Co leads industry sponsors with the highest overall number of clinical trials for glioblastoma, closely followed by Roche
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Patient segmentation
8 Symptoms
8 Risk factors
9 Diagnosis
10 TREATMENT
10 Surgery
10 Radiation therapy
10 Chemotherapy
10 Tumor-treating fields (TTFs)
11 Targeted therapy
12 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
35 RECENT EVENTS AND ANALYST OPINION
35 DNX-2401 for Glioblastoma (November 20, 2020)
36 Omburtamab for Glioblastoma (October 16, 2020)
38 AG-881 for Glioblastoma (May 29, 2020)
39 FT-2102 for Glioblastoma (May 28, 2020)
40 DB107 for Glioblastoma (September 12, 2019)
42 Opdivo for Glioblastoma (September 5, 2019)
44 KEY UPCOMING EVENTS
45 KEY REGULATORY EVENTS
45 Innovent’s Adalimumab And Bevacizumab Get New Indications In China
45 New Approvals In Spotlight As China Gears For National Congress
45 Mylan Reveals FDA Goal Date For Bevacizumab
46 PROBABILITY OF SUCCESS
47 LICENSING AND ASSET ACQUISITION DEALS
47 Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases
47 Connectyx Explores Use Of NCI Antibody For Brain Cancer
47 Telix Chooses China Grand In Greater China Alliance
47 City of Hope Licenses CTLX-CAR-T Candidate To Chimeric
48 Cytovia Obtains Rights To CytoImmune’s CAR Candidate
48 HLB Takes First Expansion Step Via Immunomic Acquisition
49 REVENUE OPPORTUNITY
50 CLINICAL TRIAL LANDSCAPE
51 Sponsors by status
52 Sponsors by phase
54 BIBLIOGRAPHY
55 Prescription information
56 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of glioblastoma, 2019–28
19 Figure 2: Overview of pipeline drugs for glioblastoma in the US
19 Figure 3: Pipeline drugs for glioblastoma, by company
20 Figure 4: Pipeline drugs for glioblastoma, by drug type
20 Figure 5: Pipeline drugs for glioblastoma, by classification
36 Figure 6: DNX-2401 for Glioblastoma (November 20, 2020): Phase II – CAPTIVE/KEYNOTE-192 – w/Keytruda
38 Figure 7: Omburtamab for Glioblastoma (October 16, 2020): Phase II/III – 101 (Neuroblastoma Central Nervous System/Leptomeningeal Metastases)
40 Figure 8: FT-2102 for Glioblastoma (May 28, 2020): Phase I/II – 2101-ONC-102
42 Figure 9: DB107 for Glioblastoma (September 12, 2019): Phase III – Toca 5 (w/Lomustine)
43 Figure 10: Opdivo for Glioblastoma (September 5, 2019): Phase III – CheckMate-548
44 Figure 11: Key upcoming events in glioblastoma
46 Figure 12: Probability of success in the solid tumors pipeline
50 Figure 13: Clinical trials in glioblastoma
50 Figure 14: Top 10 drugs for clinical trials in glioblastoma
51 Figure 15: Top 10 companies for clinical trials in glioblastoma
51 Figure 16: Trial locations in glioblastoma
52 Figure 17: Glioblastoma trials status
53 Figure 18: Glioblastoma trials sponsors, by phase
LIST OF TABLES
13 Table 1: Global incident cases of glioblastoma, 2019–28
15 Table 2: Incident cases of glioblastoma, by gender, 2019
17 Table 3: Marketed drugs for glioblastoma
21 Table 4: Pipeline drugs for glioblastoma in the US
35 Table 5: DNX-2401 for Glioblastoma (November 20, 2020)
37 Table 6: Omburtamab for Glioblastoma (October 16, 2020)
38 Table 7: AG-881 for Glioblastoma (May 29, 2020)
39 Table 8: FT-2102 for Glioblastoma (May 28, 2020)
41 Table 9: DB107 for Glioblastoma (September 12, 2019)
42 Table 10: Opdivo for Glioblastoma (September 5, 2019)
49 Table 11: Historical global sales, by drug ($m), 2015–19
49 Table 12: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Human Papillomavirus (HPV) Vaccines 
Sign up to the